» Articles » PMID: 39930275

Deep Learning Radiomics for Survival Prediction in Non-Small-Cell Lung Cancer Patients from CT Images

Overview
Journal J Med Syst
Date 2025 Feb 10
PMID 39930275
Authors
Affiliations
Soon will be listed here.
Abstract

This study aims to apply a multi-modal approach of the deep learning method for survival prediction in patients with non-small-cell lung cancer (NSCLC) using CT-based radiomics. We utilized two public data sets from the Cancer Imaging Archive (TCIA) comprising NSCLC patients, 420 patients and 516 patients for Lung 1 training and Lung 2 testing, respectively. A 3D convolutional neural network (CNN) survival was applied to extract 256 deep-radiomics features for each patient from a CT scan. Feature selection steps are used to choose the radiomics signatures highly associated with overall survival. Deep-radiomics and traditional-radiomics signatures, and clinical parameters were fed into the DeepSurv neural network. The C-index was used to evaluate the model's effectiveness. In the Lung 1 training set, the model combining traditional-radiomics and deep-radiomics performs better than the single parameter models, and models that combine all three markers (traditional-radiomics, deep-radiomics, and clinical) are most effective with C-index 0.641 for Cox proportional hazards (Cox-PH) and 0.733 for DeepSurv approach. In the Lung 2 testing set, the model combining traditional-radiomics, deep-radiomics, and clinical obtained a C-index of 0.746 for Cox-PH and 0.751 for DeepSurv approach. The DeepSurv method improves the model's prediction compared to the Cox-PH, and models that combine all three parameters with the DeepSurv have the highest efficiency in training and testing data sets (C-index: 0.733 and 0.751, respectively). DeepSurv CT-based deep-radiomics method outperformed Cox-PH in survival prediction of patients with NSCLC patients. Models' efficiency is increased when combining multi parameters.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Pao W, Girard N . New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2):175-80. DOI: 10.1016/S1470-2045(10)70087-5. View

3.
Aerts H . The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review. JAMA Oncol. 2016; 2(12):1636-1642. DOI: 10.1001/jamaoncol.2016.2631. View

4.
Aerts H, Velazquez E, Leijenaar R, Parmar C, Grossmann P, Carvalho S . Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014; 5:4006. PMC: 4059926. DOI: 10.1038/ncomms5006. View

5.
Li H, Zhang R, Wang S, Fang M, Zhu Y, Hu Z . CT-Based Radiomic Signature as a Prognostic Factor in Stage IV -Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study. Front Oncol. 2020; 10:57. PMC: 7040202. DOI: 10.3389/fonc.2020.00057. View